The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Peak study: A phase 3, randomized, open-label multicenter clinical study of bezuclastinib (CGT9486) and sunitinib in combination versus sunitinib in patients with gastrointestinal stromal tumors (GIST).
 
Michael C. Heinrich
Honoraria - Novartis
Consulting or Advisory Role - Cogent Pharmaceuticals; Deciphera; Novartis; Theseus Pharmaceuticals
Research Funding - Cogent Biosciences
Patents, Royalties, Other Intellectual Property - Patent on treatment of GIST-licensed to Novartis (Inst)
 
Neeta Somaiah
Stock and Other Ownership Interests - JNJ (I); Pfizer (I)
Consulting or Advisory Role - AADi; Bayer; Blueprint Medicines; Boehringer Ingelheim; Deciphera; Epizyme
Research Funding - Advenc; Ascentage Pharma; AstraZeneca/MedImmune (Inst); Cogent Biosciences; Daiichi Sankyo/Lilly; Deciphera; GlaxoSmithKline; Karyopharm Therapeutics
 
Jonathan C. Trent
Consulting or Advisory Role - AADi; Agios; Bayer; Blueprint Medicines; Boehringer Ingelheim; C4 Therapeutics; Cogent Medicine; Daiichi Sankyo; Deciphera; Epizyme; Foghorn Therapeutics; SERVIER
 
Breelyn A. Wilky
Consulting or Advisory Role - AADi; Adcendo; Boehringer Ingelheim; Deciphera; Epizyme; Polaris; SpringWorks Therapeutics
Research Funding - Exelixis
Travel, Accommodations, Expenses - Agenus
 
Melissa Amber Burgess
Consulting or Advisory Role - Rain Therapeutics; SpringWorks Therapeutics
Research Funding - Merck
 
Arun S. Singh
Leadership - Certis Oncology Solutions
Stock and Other Ownership Interests - AntiCancer; Certis Oncology Solutions
Honoraria - Galvanize Therapeutics
Consulting or Advisory Role - Bayer; Daiichi Sankyo; Lilly
Speakers' Bureau - AADi; Ayala Pharmaceuticals (Inst); Daiichi Sankyo; Deciphera; Eisai; Lilly; MJH Life Sciences; Novartis; RAIN Therapeutics (Inst); Scripps Health; TRACON Pharma (Inst)
Research Funding - Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); deciphera (Inst); Lilly (Inst); Nanocarrier (Inst); TRACON Pharma (Inst)
Travel, Accommodations, Expenses - Daiichi Sankyo; Deciphera; Eisai; Galvanize Therapeutics; Lilly; Novartis
Other Relationship - Certis Oncology Solutions
 
Steven Attia
Research Funding - AB Science (Inst); Adaptimmune (Inst); Advenchen Laboratories (Inst); Ayala Pharmaceuticals (Inst); Bavarian Nordic (Inst); Bayer (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); BTG (Inst); C4 Therapeutics (Inst); CBA Pharma (Inst); Deciphera (Inst); Desmoid Tumor Research Foundation; Epizyme (Inst); FORMA Therapeutics (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Gradalis (Inst); Incyte (Inst); InhibRx (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Merck (Inst); Monopar Therapeutics (Inst); Novartis (Inst); Noxopharm (Inst); Philogen (Inst); PTC Therapeutics (Inst); Rain Therapeutics (Inst); Salarius Pharmaceuticals (Inst); SpringWorks Therapeutics (Inst); Takeda (Inst); Theseus Pharmaceuticals (Inst); TRACON Pharma (Inst); TRACON Pharma (Inst); Trillium Therapeutics (Inst)
 
Mark Agulnik
Consulting or Advisory Role - AADi; Coherus Biosciences; Regeneron
Speakers' Bureau - Bayer; Deciphera
Research Funding - Exelixis (Inst)
 
William D. Tap
Leadership - AstraZeneca; Atropos; Certis Oncology Solutions; Innovo Therapeutics
Stock and Other Ownership Interests - Atropos; Certis Oncology Solutions
Consulting or Advisory Role - Adcendo; Amgen; AmMax Bio; Ayala Pharmaceuticals; Bayer; BioAtla; Boehringer Ingelheim; Cogent Biosciences; Daiichi Sankyo; Deciphera; Epizyme; Foghorn Therapeutics; inhibrx; Kowa Pharmaceutical; Lilly; Medpacto; PharmaEssential; Servier
Research Funding - Avacta Life Sciences (Inst); BioAtla (Inst); Blueprint Medicines (Inst); C4 Therapeutics (Inst); Cogent Biosciences (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Theseus Pharmaceuticals (Inst)
Patents, Royalties, Other Intellectual Property - Companion Diagnostic for CDK4 inhibitors - 14/854,329; Enigma and CDH18 as companion Diagnostics for CDK4 inhibition – SKI2016-021-03
 
Sebastian Bauer
Honoraria - Deciphera; GlaxoSmithKline; Novartis; Pharmamar
Consulting or Advisory Role - ADC Therapeutics; Adcendo; Bayer; Blueprint Medicines; Boehringer Ingelheim; Daiichi Sankyo; Deciphera; Exelixis; GlaxoSmithKline; IDRX; Janssen-Cilag; Lilly; Mundipharma; Nanobiotix
Research Funding - Blueprint Medicines; Incyte (Inst); Novartis
Travel, Accommodations, Expenses - Pharmamar
 
Robin Lewis Jones
Consulting or Advisory Role - Adaptimmune; Athenex; Bayer; Blueprint Medicines; Boehringer Ingelheim; Boehringer Ingelheim; Clinigen Group; Daiichi Sankyo; Deciphera; Eisai; Epizyme; Immodulon Therapeutics; Immune Design; Immunicum; Karma Oncology; Lilly; Merck Serono; Morphotek; Mundipharma; PharmaMar; SpringWorks Therapeutics; SynOX; TRACON Pharma; UpToDate
Research Funding - GlaxoSmithKline (Inst)
Travel, Accommodations, Expenses - PharmaMar
 
Cesar Serrano
Honoraria - Deciphera; PharmaMar; Roche
Consulting or Advisory Role - Blueprint Medicines; Cogent Biosciences; Deciphera; IDRX; Immunicum; NewBay Pharma
Research Funding - IDRX (Inst); Karyopharm Therapeutics (Inst)
Travel, Accommodations, Expenses - Bayer; Gilead Sciences; Pfizer; PharmaMar
 
Liangxing Zou
Employment - Cogent Biosciences
Stock and Other Ownership Interests - Cogent Biosciences
 
Kevin Moynihan
Employment - Cogent Biosciences
Stock and Other Ownership Interests - Cogent Biosciences
 
Julia Lawrence
Employment - Cogent Biosciences
Stock and Other Ownership Interests - Cogent Biosciences
 
Andrew J. Wagner
Consulting or Advisory Role - AADi; BioAtla; Boehringer Ingelheim; Cogent Biosciences; Daiichi Sankyo; Deciphera; InhibRx; Lilly; Mundipharma; SERVIER
Research Funding - AADi (Inst); Cogent Biosciences (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Foghorn Therapeutics (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Plexxikon (Inst); Rain Therapeutics (Inst)